Secure Early Market Dominance Global biopharmaceutical sponsors must continually optimize their regulatory strategies to accelerate time-to-market and secure competitive advantages. The U.S. FDA utilizes Expedited Review Programs to incentivize innovation in areas of profound unmet medical need. While traditional statutory Priority Review Vouchers (PRVs) have successfully served as transferable, non-dilutive funding vehicles for over a [...]